Press Releases.

Month Year

Month Year

Investor Alerts

November 03, 2014

Regulus Announces Closing of Public Offering of $103.5M of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
October 30, 2014

Regulus Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call
October 28, 2014

Regulus Announces Pricing of Public Offering of Common Stock
October 27, 2014

Regulus Announces Commencement of Public Offering of Common Stock
October 22, 2014

A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment History

- Interim Results from Ongoing Study Demonstrate Human Proof-of-Concept and Underscore the Value of Regulus' microRNA Platform -
October 14, 2014

Regulus Presents New Preclinical Data on Multiple Programs and Provides Portfolio Overview at 10th Annual Oligonucleotide Therapeutics Society (OTS) Meeting

-New Preclinical Results Increase Mechanistic Understanding of Targeting miR-103/107 for Metabolic Disorders and miR-21 for Renal Dysfunction in Alport Syndrome Patients-
September 24, 2014

Regulus Announces Notice of Allowance from U.S. Patent Office Related to microRNA-103/107 Program in Metabolic Disorders

-Newly Allowed Claims Demonstrate Regulus' Leadership in the microRNA Field-
September 18, 2014

Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients

-ATHENA to Shed Light on Rare, Life-Threatening Kidney Disease -
August 07, 2014

Regulus to Present at the Wedbush Life Sciences Management Access Conference
August 06, 2014

Regulus Reports Second Quarter 2014 Financial Results and Recent Highlights

- 'Clinical Map Initiative' On Track; Human Proof of Concept Results for RG-101 and Nomination of Third Clinical Candidate Expected by YE 2014 -

Show per page